Quick Takeaways
- GOLDMAN SACHS GROUP INC filed SCHEDULE 13G for SYNDAX PHARMACEUTICALS, INC. Common Stock (SNDX).
- Disclosed ownership: 7%.
- Date of event: 31 Dec 2024.
GOLDMAN SACHS GROUP INC - 31 Dec 2024 SCHEDULE 13G Report for SYNDAX PHARMACEUTICALS, INC. Common Stock (SNDX)
- Filing Manager
- GOLDMAN SACHS GROUP INC
- Reporting Manager
- THE GOLDMAN SACHS GROUP, INC.
- Symbol
- SNDX
- Shares outstanding
- 85,049,503 shares
- Disclosed Ownership
- 5,953,465 shares
- Ownership
- 7%
- Form type
- SCHEDULE 13G
- Filing time
- 12 Feb 2025, 11:39:31 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 09 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GOLDMAN SACHS GROUP INC disclosed 7% ownership in SYNDAX PHARMACEUTICALS, INC. Common Stock (SNDX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Feb 2025, 11:39.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | 7% | 5,953,465 | 0 | 5,953,202 | Name: Ameen Soetan | Attorney-in-fact | |
| GOLDMAN SACHS & CO. LLC | 7% | 5,953,465 | 0 | 5,953,202 | Name: Ameen Soetan | Attorney-in-fact |